151386-97-9

Upstream product

• 151386-46-8 1-N-(adamant-1-ylmethyl)-3-amino-2,4-dioxo-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 67531-68-4 ethyl 3-isocyanatobenzoate 
• 40426-24-2 ((3r,5r,7r)-adamantan-1-yl)methyl methanesulfonate 
• 22316-50-3 1-phenyl 1,2,4,5-tetrahydro 2,4-dioxo 3H-1,5-benzodiazepine 
• 151386-39-9 2-(adamant-2-ylmethyl)aminodiphenylamine 
• 151385-95-4 1-N-(adamant-1-ylmethyl)-2,4-dioxo-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151620-72-3 1-N-(adamant-1-ylmethyl)-3-azido-2,4-dioxo-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151386-40-2 1-(adamant-2-ylmethyl)-2,4-dioxo-5-phenyl-3-phenylhydrazono-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 534-85-0 N-phenyl-1,2-benzenediamine 

Relevant academic research and scientific papers

Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazephines as cholecystokinin-B receptor antagonists

A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective C

1,5-benzodiazepine derivatives

The present invention relates to compounds of formula (I) which are antagonists of gastrin and CCK-B receptors. The compounds of formula (I) are 1,5-benzodiazepine derivatives. STR1